6. Identification of a novel drug resistance determinant resulting in global change of attitude and policy
Submitting Institution
Cardiff UniversityUnit of Assessment
Clinical MedicineSummary Impact Type
PoliticalResearch Subject Area(s)
Medical and Health Sciences: Medical Microbiology
Summary of the impact
Cardiff Researchers in 2009 discovered the new antibiotic resistance
determinant NDM-1 and in 2010/11 characterised its rapid worldwide spread
through Gram-negative bacteria (e.g. Escherichia coli and Vibrio
cholerae). NDM-1 redefined how antibiotic resistance can
spread locally and internationally and create new extensively-drug
resistance (XDR) that severely limits therapeutic options. This discovery
has resulted in: 1) new policies for the admission of overseas patients to
hospitals in the UK, France, USA, Australia and China, 2) linkage between
MDR transmission and poor sewerage treatment, 3) potable water treatment
in Southern Asia 4) positioning papers for the World Health Assembly and
5) policy-changes by the World Health Organisation.
Underpinning research
The problem of antibiotic resistance is listed as the WHO's key concern
for the 21stC - the increasing resistance to the most potent
drugs and the lack of new antibiotics being developed is heralding in an
era of untreatable infections. These sentiments have been recently echoed
by CMO, Prof. Sally Davies. Bacterial enzymes that break down antibiotics
such as penicillin are termed f062-lactamases and a sub-group, termed
carbapenemases break down the latest and most clinically useful group of
these antibiotics, carbapenems. The most potent of these enzymes are
metallo-f062-lactamases (MBL) as there are no clinical inhibitors for
these enzymes. In 2008, Timothy Walsh (Head of Microbiology Research, in
post since 2006) and Mark Toleman (Research Fellow, in Cardiff since 2007
and now Senior Lecturer) discovered and characterised a novel MBL, called
New Delhi Metallo-03b2-lactamase (NDM-1)3.1 The
hospitalised patient, a native Indian but Swedish resident, had just
returned to Stockholm from New Delhi. Collaborative studies in India
(Chennai and Haryana) initiated and funded by joint Welcome grant awarded
to Walsh and Toleman indicated that the NDM-1 gene was present in approx.
8% of clinical bacterial isolates f in the South and 13% in the north of
India. 3.2 NDM-1 is unique in structure, genetic
context, clinical epidemiology, and has spread globally more rapidly than
any other type of antibiotic resistance. 3.3, 3.4 In
September 2010 Walsh collaborated with Channel 4 journalists who were
making a documentary on the use of antibiotics in India and obtained water
and out-flow seepage samples. This work showed that the Indian environment
was significantly contaminated with NDM-1 positive bacteria. 3.5
The work on NDM-1 marked a seminal change in our global understanding of
antibiotic resistance. The key findings of the work were:
- NDM-1 was clearly widespread in the Southern Asian community as well
as hospitals making this very different from other types of antibiotic
resistance. 3.2,3.5
- Genetic context, structure and the aetiology of the NDM-1 gene is
unique. 3.5
- The success of NDM-1 spreading through diverse bacterial species has
been unparalleled in antibiotic resistance and related to their highly
promiscuous plasmids. 3.5
- Transfer of these plasmids transforms sensitive bacterial strains
into extreme drug resistant types only being sensitive to colistin and
tigecycline. 3.2,3.5
- Global travel and in particular overseas surgery were a high-risk
factor in presenting with NDM-1. 3.2,3.6
All work initially carried out on NDM-1, and 90% of the molecular
characterisation in the clinical epidemiology study was performed at
Cardiff University. Walsh and Toleman were the first to report NDM-1 in
key human pathogens such as Shigella spp. and Vibrio cholerae
(1, 2). These findings have influenced infection control policies in UK
hospitals for the isolation of NDM-1 positive pathogens as recently
reported in the Lancet. 3.6 They are currently co-ordinating
the biggest clinical trial to date in Southern Asia (Karachi) (funded by
Walsh's charitable foundation called SAARRP) to assess the
clinical significance of NDM-1 positive bacteria. Preliminary data from
this trial shows that 31% of patients admitted to public hospitals and 32%
on discharge carry NDM-1 bacteria as gut flora. Toleman's work in
Bangladesh has also found NDM in 60% of environmental water samples These
data when extrapolated to the whole of Southern Asia would suggest that
nearly 1 billion people could be carrying NDM-1 positive bacteria.
References to the research
3.1 Yong, Y., Toleman, M.A., Weeks, J., Giske, C., Walsh, T.R.
(2009) Characterisation of a new metallo-β-lactamase gene, blaNDM-1,
and a novel erythromycin esterase gene carried on a unique genetic
structure in Klebsiella pneumoniae sequence Type 14 from India. Antimicrob.
Agents and Chemother. 53, 5046-54. DOI: 10.1128/AAC.00774-09 (cited
approx. 100 times).
3.2 Kumarasamy, K.K., Toleman, M.A., Walsh, T.R., I
(2010). Emergence of a new antibiotic resistance mechanism in India,
Pakistan, and the UK: a molecular, biological, and epidemiological study.
Lancet Infect Dis. 10, 597-602. DOI: 10.1016/S1473- 3099(10)70143-2
(cited >600 times).
3.3 Hammerum, A.M., Toleman, M.A., Hansen, F., Kristensen, B.,
Lester, C.H., Walsh, T.R., Fuursted, K. (2010). Global spread of
New Delhi metallo-03b2-lactamase1.Lancet Infect Dis. 10, 829-30.
DOI: 10.1016/S1473-3099(10)70276-0
3.4 Toleman, M. A., Spencer, J., Jones, L., Walsh, T.R.
(2012). blaNDM-1 is a chimera likely
constructed in Acinetobacter baumannii. Antimicrob Agents
Chemother. 56, 2773-6. DOI: 10.1128/AAC.06297-11
3.5 Walsh, T.R., Weeks, J., Livermore, D.M., Toleman, M.A.
(2011). Dissemination of NDM-1 positive bacteria in the New Delhi
environment and its implications for human health: an environmental point
prevalence study. Lancet Infect Dis. 11, 355-62. DOI:
10.1016/S1473- 3099(11)70059-7 (cited >130 times)
3.6 Darley, E., Jones, L., Daniels, V., Wootton, M., MacGowan, A.P., Walsh,
T.R. (2012). NDM-1 polymicrobial infections including Vibrio
cholerae. Lancet. 380 (9850), 1358. DOI:
10.1016/S0140-6736(12)60911-8
Details of the impact
Health Policy Changes: In November 2009, Walsh and Toleman were
part of a UK-wide Department of Health (DoH) call alerting all UK
hospitals and departments (through the Public Health England Reference
Laboratory) to this new type of antibiotic resistance.5.1 Their
NDM-1 studies were used to invoke mandatory screening be conducted for all
patients arriving from overseas hospitals - these proposals were fully
adopted by the UK DoH. 5.1 The ECDC called for greater
surveillance and enhanced European-wide infection control measures to
contain the threat of NDM-1 - see Table 2 of reference 5.2. In South
Africa, the National Institute for Communicable Diseases issued a
nationwide alert calling for increased infection control measures due to
NDM-1. 5.3 In Canada (through governmental agency
focusing on practice and policy interventions for Canadian populations),
alerts and altered policies have been implemented. 5.4
In August 2010 as a direct response to the first publication, the
Ministry of Health and Family Welfare together with the National Centre
for Disease Control in India constituted a National Task Force for the
containment of Antimicrobial resistance. In March 2011, this task force
produced India's first ever national antibiotic policy document entitled "National
Policy for Containment of Antimicrobial Resistance in India" (http://nicd.nic.in/ab_policy.pdf).
In August 2012, all major Indian clinical, academic and research bodies
met in Chennai to discuss for the first time implementing 1. Antibiotic
stewardship. 2. Infection control and 3. National Surveillance. This
document, entitled "The Chennai Declaration - A Roadmap to tackle the
Challenge of Antimicrobial Resistance", is a direct response to
studies in India, led by Walsh and Toleman that have persuaded the Indian
government to acknowledge the very serious antibiotic resistance issues.5.5
Walsh is advising the authors of the Chennai declaration and the Pakistani
health authorities on antibiotic stewardship and infection control issues.
IMPACT: Prevention of the spread of NDM-1 bacteria throughout UK
hospital wards as witnessed by the recent example published in the Lancet
and International policy changes e.g. India.5.1-5.5
Public Behaviour Changes: These studies encouraged the Indian
government to take antibiotic resistance more seriously. The work was the
catalyst for the Indian government to organise emergency meetings
resulting in the publication of the first Indian Government policies on
tackling antibiotic resistance. The subsequent Chennai agreement has time
lined a road map for implementation of antibiotic stewardship and
infection control programs in response to Walsh's description of the
issues of multi-drug resistance in India - these are currently being
implemented across all of India so their impact is yet to be assessed.5.5
A secondary behaviour change has resulted from the work because it
highlights the threat posed by the growing industry of medical tourism and
international cosmetic surgery; this has caused clashes with Indian
private hospitals undertaking cosmetic surgery.
IMPACT: As a direct result of the research, stricter control of
antibiotic stewardship and national infection control programs are being
implemented in India. The research highlighted some of the medical issues,
i.e. post-surgical infections, associated with medical tourism.
Public Awareness of a Health Risk: Immediately following
publication of the seminal paper in Lancet Infectious Diseases,
NDM-1 was the fourth biggest story world-wide, the lead story on the BBC 6
o'clock news 5.6 and broadcasted by ABC, CNN,
Al-Jazeera, China-TV, India Today, SKY, ITV, Channel 4 and Channel 5. On
11th August, 2010 the NDM-1 story was covered on the front
pages of the Telegraph, Independent, Guardian, Mail, Times, Financial
Times, Sun and Mirror.5.6-5.8 Interviews with the
Telegraph, Times, Guardian and Independent provided informed editorials in
the weekend editions5.6-5.8 On the web, the NDM-1
feature registered 4.7 million internet hits in 2 days (11th-12th
August). Moreover, the follow-up study published in April 2011 was
covered widely in India and internationally including by the BBC - this
was the first study linking the emergence of "superbugs" to the lack of
sanitation in developing countries. This study was covered at the time by
a Channel 4 documentary and more recently by BBC Horizon and ABC public
awareness programs.5.9, 5.10
IMPACT: This global coverage changed the public's perception of
"superbugs" and demonstrated that resistance can be readily spread from
one bacterium to another - a clear demarcation from MRSA and "C.
difficile". This perception resulted in international alerts by the
Communicable Disease Centre (CDC) (USA), European CDC (ECDC) World Health
Organisation (WHO) etc. and resulted in global behavioural and policy
changes.
The Control of Diseases has Changed. The follow up study
describing the discovery of NDM-1 in the Indian tap-water and environment
has directly led to the Indian government issuing chlorine tablets to
sanitise tap water for New Delhi residents unable to afford bottled water.3.6
This practice continues, although control studies have not been undertaken
in India to assess the impact of the intervention.
IMPACT: Introduction of potable water treatment in New Delhi.
Impact on National and International Organisations: The impact of
NDM-1 has been detailed by many international health organisations
including: Individual national governments (China, Korea, France, USA and
UK) 5.1-5.5, the European Society of Clinical Microbiology and
Infectious Diseases, (CDC) (USA), WHO, European Parliament, and World
Health Assembly. As a result of this international interest,
Walsh has been invited to give over 46 international talks (including
Australia, Norway, China, USA, Canada, Saudi Arabia, Thailand, Vietnam,
Japan, Pakistan and India) and Toleman has given talks in Italy,
Switzerland, Austria, USA, Saudi Arabia, and the UK. Walsh has addressed
the European parliament with the director of the WHO, Margaret Chan (http://www.who.int/dg/speeches/2012/amr_20120314/en/
available on request from HEI) on NDM-1; Toleman has addressed NATO
surgeons at the NATO headquarters in Brussels. Walsh has recently been
asked by the WHO and the Chinese CDC to act as a consultant on
international antibiotic resistance surveillance and was asked to become a
member on the World Health Associated infections forum (http://www.hai-forum.com/ webcast). Walsh has also been asked by the UK government
"GoScience" to write a positioning paper predicting resistance rates in
2030 and its impact on human health. .
IMPACT: Mission statements and general alerts on the impact of
NDM-1 issued by the above organisations including national screening
programs.
Outcomes for Patients have Improved: The research on NDM-1 has
altered treatment of individuals presenting with NDM-1 positive
infections. The work documenting NDM-1 resistance profiles and prevention
measures for spread is known throughout the UK.5.1 A
recent case was of a traveller from India who required emergency admission
in at Southmead Hospital, Bristol. Treatment as above prevented further
spread of NDM-1 pathogens.3.6
IMPACT: Production of guidelines, in collaboration with the HPA,
for patient treatment and management. Less harm to patients, limited
spread of "superbugs" in UK hospitals and reduced costs.3.6
Sources to corroborate the impact
5.1 UK:
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1248854045473 (Backs
up claim of involvement in UK health policy changes and available on
request from HEI)
5.2 Europe-wide:
http://www.eurosurveillance.org/ViewArticle.aspx?Articleid=19716
(Backs up claim of involvement in EU health policy changes and available
on request from HEI)
5.3 South Africa: National Institute for Communicable Diseases
http://www.nhls.ac.za/?page=alerts&id=5&rid=110
(Backs up claim of South African health policy changes and available on
request from HEI)
5.4 Canada: http://www.nccid.ca/the-w-5-of-ndm-1
(Backs up claim of involvement in Canadian health policy changes and
available on request from HEI).
5.5 Ghafur, A., et al. "The Chennai Declaration." Indian J
Cancer 2012. 49; DOI:10.4103/0019-509X.104065 (backs up claims of
Health Policy Changes, Public behaviour changes and public awareness of
health risks).
5.6 BBC news. http://www.bbc.co.uk/news/health-10930031)
(backs up claims of raising public awareness of a health risk)
5.7 Telegraph (http://www.guardian.co.uk/science/2010/aug/11/antibiotics-efficiency-drug-
resistant-bacteria) (backs up claims of raising public awareness of
a health risk)
5.8 Guardian (http://www.dailymail.co.uk/health/article-1302358/NDM-1-Were-blame-
indestructible-Indian-superbug.html) (backs up claims of raising
public awareness of a health risk)
5.9 BBC horizon (www.bbc.co.uk/programmes/b01ms5c6
television clips) (backs up claims of raising public awareness of a health
risk)
5.10 ABC 7.30 documentary. (http://www.abc.net.au/7.30/content/2013/s3810324.htm)
(backs up claims of raising public awareness of a health risk)